Fate Therapeutics (FATE)
(Real Time Quote from BATS)
$3.70 USD
-0.06 (-1.60%)
Updated Jun 14, 2024 11:08 AM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
Fate Therapeutics, Inc. [FATE]
Reports for Purchase
Showing records 361 - 380 ( 433 total )
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - The A to Z of HSCT: Investor?s guide to Hematopoietic Transplant Medicine
Provider: Roth Capital Partners, Inc.
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - 2016 PacGrow Healthcare Conference Day 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology/Biopharmaceuticals - 2016 PacGrow Healthcare Conference Day 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q16: Fate May Have Two New Programs in the Clinic in 2017
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2 EPS; ProTmune Study Underway; Pipeline Programs Advance Towards Clinic in Early 2017
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A Tech Stacked Deck; Assuming Coverage With a Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 30
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q, Expecting Valuation Disconnect to Correct with ProTmune Data this Year, Reiterate OP
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q15 Update: ProTmune Preparing to Enter Clinic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q15: Focus is on ProTmune Development as FATE Completes Year of Transition, Reiterate OP but Reducing PT to $8 (from $10) on Dilution Concerns
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Best of Both Worlds in Hematopoietic Transplant: Delivering Graft-vs-Leukemia Activity with Low Graft-vs-Host Risk
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Spotlight on Cell and Gene Therapy at ASH 2015
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Punting on ProHema, ProTmune Takes Center Stage; Revising PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASH Update Supports ProTmune Development, In Human Study to Start in 2016, Reiterate Outperform
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASH Update Supports ProTmune Development, In Human Study to Start in 2016, Reiterate Outperform
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 7th
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 23
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q15 Update: Evolving Pipeline Places Emphasis on Fully-Customizable Cellular Immunotherapies
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M